CARsgen Therapeutics Holdings Limited (OTCMKTS:CRTHF – Get Free Report) shares traded down 16.7% during trading on Wednesday. The company traded as low as $1.35 and last traded at $1.35. Approximately 2,300 shares changed hands during trading, a decline of 10% from the average daily volume of 2,544 shares. The stock had previously closed at $1.62.
CARsgen Therapeutics Price Performance
The company has a fifty day moving average price of $1.61 and a two-hundred day moving average price of $1.74.
About CARsgen Therapeutics
CARsgen Therapeutics is a biotechnology company focused on developing cell therapies for cancer, particularly chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company conducts research and development and has operations in China and the United States. Its lead therapy, zevor-cel (CT053), is an autologous CAR T-cell treatment targeting BCMA for relapsed or refractory multiple myeloma. It received approval in China in 2024. CARsgen is also developing candidates for solid tumors, including CT041, which targets CLDN18.2. Founder Zonghai Li leads the company as chairman and chief executive officer.
Featured Articles
- Five stocks we like better than CARsgen Therapeutics
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for CARsgen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CARsgen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
